Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 282

1.

Percutaneous ethanol injection for liver metastases.

Swierz MJ, Storman D, Riemsma RP, Wolff R, Mitus JW, Pedziwiatr M, Kleijnen J, Bala MM.

Cochrane Database Syst Rev. 2020 Feb 4;2:CD008717. doi: 10.1002/14651858.CD008717.pub3. Review.

PMID:
32017845
2.

Durvalumab for the Treatment of Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Witlox WJA, van Asselt ADI, Wolff R, Armstrong N, Worthy G, Chalker A, Buksnys T, Stirk L, Kleijnen J, Joore MA, Grimm SE.

Pharmacoeconomics. 2019 Dec 9. doi: 10.1007/s40273-019-00870-w. [Epub ahead of print] Review.

PMID:
31814080
3.

The impact of interpregnancy weight change on perinatal outcomes in women and their children: A systematic review and meta-analysis.

Timmermans YEG, van de Kant KDG, Oosterman EO, Spaanderman MEA, Villamor-Martinez E, Kleijnen J, Vreugdenhil ACE.

Obes Rev. 2020 Mar;21(3):e12974. doi: 10.1111/obr.12974. Epub 2019 Nov 21. Review.

PMID:
31751496
4.

Fluocinolone Acetonide Intravitreal Implant for Treating Recurrent Non-infectious Uveitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Pouwels XGLV, Petersohn S, Carrera VH, Denniston AK, Chalker A, Raatz H, Armstrong N, Shah D, Witlox W, Worthy G, Noake C, Riemsma R, Kleijnen J, Joore MA.

Pharmacoeconomics. 2019 Nov 8. doi: 10.1007/s40273-019-00851-z. [Epub ahead of print] Review.

PMID:
31701471
5.

Effect of DNA damage response mutations on prostate cancer prognosis: a systematic review.

Swift SL, Lang SH, White H, Misso K, Kleijnen J, Quek RG.

Future Oncol. 2019 Oct;15(28):3283-3303. doi: 10.2217/fon-2019-0298. Epub 2019 Sep 19.

6.

Systematic review and network meta-analysis of the efficacy and safety of lidocaine 700 mg medicated plaster vs. pregabalin.

Buksnys T, Armstrong N, Worthy G, Sabatschus I, Boesl I, Buchheister B, Swift SL, Noake C, Huertas Carrera V, Ryder S, Shah D, Liedgens H, Kleijnen J.

Curr Med Res Opin. 2020 Jan;36(1):101-115. doi: 10.1080/03007995.2019.1662687. Epub 2019 Sep 12.

PMID:
31469302
7.

Sarcopenia and ovarian cancer survival: a systematic review and meta-analysis.

Ubachs J, Ziemons J, Minis-Rutten IJG, Kruitwagen RFPM, Kleijnen J, Lambrechts S, Olde Damink SWM, Rensen SS, Van Gorp T.

J Cachexia Sarcopenia Muscle. 2019 Dec;10(6):1165-1174. doi: 10.1002/jcsm.12468. Epub 2019 Aug 7. Review.

8.

A systematic review of the prevalence of DNA damage response gene mutations in prostate cancer.

Lang SH, Swift SL, White H, Misso K, Kleijnen J, Quek RGW.

Int J Oncol. 2019 Sep;55(3):597-616. doi: 10.3892/ijo.2019.4842. Epub 2019 Jul 16.

9.

Cryotherapy for liver metastases.

Bala MM, Riemsma RP, Wolff R, Pedziwiatr M, Mitus JW, Storman D, Swierz MJ, Kleijnen J.

Cochrane Database Syst Rev. 2019 Jul 10;7:CD009058. doi: 10.1002/14651858.CD009058.pub3.

PMID:
31291464
10.

The Effect of Supervised Exercise, Home Based Exercise and Endovascular Revascularisation on Physical Activity in Patients With Intermittent Claudication: A Network Meta-analysis.

van den Houten MML, Hageman D, Gommans LNM, Kleijnen J, Scheltinga MRM, Teijink JAW.

Eur J Vasc Endovasc Surg. 2019 Sep;58(3):383-392. doi: 10.1016/j.ejvs.2018.12.023. Epub 2019 Jun 21. Review.

PMID:
31235306
11.

The effect of exercise therapy combined with psychological therapy on physical activity and quality of life in patients with painful diabetic neuropathy: a systematic review.

van Laake-Geelen CCM, Smeets RJEM, Quadflieg SPAB, Kleijnen J, Verbunt JA.

Scand J Pain. 2019 Jul 26;19(3):433-439. doi: 10.1515/sjpain-2019-0001.

PMID:
31112511
12.

A Systematic Review of Direct Cardiovascular Event Costs: An International Perspective.

Ryder S, Fox K, Rane P, Armstrong N, Wei CY, Deshpande S, Stirk L, Qian Y, Kleijnen J.

Pharmacoeconomics. 2019 Jul;37(7):895-919. doi: 10.1007/s40273-019-00795-4. Review.

PMID:
30949988
13.

Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Grimm SE, Fayter D, Ramaekers BLT, Petersohn S, Riemsma R, Armstrong N, Pouwels X, Witlox W, Noake C, Worthy G, Kleijnen J, Joore MA.

Pharmacoeconomics. 2019 Oct;37(10):1195-1207. doi: 10.1007/s40273-019-00792-7. Review.

14.

Cost-conscious high-quality care and guideline development education: a strange contradiction or simple solution?

Majoie HJM, van Gaalen J, Verstegen DML, van Mastrigt GAPG, Kleijnen J, Alonso-Coello P, Gartlehner G, Ritchie K, Service D, Leone M, Evers SMAA.

Eur J Neurol. 2019 Apr;26(4):e48-e49. doi: 10.1111/ene.13855. No abstract available.

PMID:
30829458
15.

Prevention of Cervical Cancer: Guideline of the DGGG and the DKG (S3 Level, AWMF Register Number 015/027OL, December 2017) - Part 2 on Triage, Treatment and Follow-up.

Hillemanns P, Friese K, Dannecker C, Klug S, Seifert U, Iftner T, Hädicke J, Löning T, Horn L, Schmidt D, Ikenberg H, Steiner M, Freitag U, Siebert U, Sroczynski G, Sauerbrei W, Beckmann MW, Gebhardt M, Friedrich M, Münstedt K, Schneider A, Kaufmann A, Petry KU, Schäfer APA, Pawlita M, Weis J, Mehnert A, Fehr M, Grimm C, Reich O, Arbyn M, Kleijnen J, Wesselmann S, Nothacker M, Follmann M, Langer T, Jentschke M.

Geburtshilfe Frauenheilkd. 2019 Feb;79(2):160-176. doi: 10.1055/a-0828-7722. Epub 2019 Feb 18.

16.

Prevention of Cervical Cancer: Guideline of the DGGG and the DKG (S3 Level, AWMF Register Number 015/027OL, December 2017) - Part 1 with Introduction, Screening and the Pathology of Cervical Dysplasia.

Hillemanns P, Friese K, Dannecker C, Klug S, Seifert U, Iftner T, Hädicke J, Löning T, Horn L, Schmidt D, Ikenberg H, Steiner M, Freitag U, Siebert U, Sroczynski G, Sauerbrei W, Beckmann MW, Gebhardt M, Friedrich M, Münstedt K, Schneider A, Kaufmann A, Petry KU, Schäfer APA, Pawlita M, Weis J, Mehnert A, Fehr M, Grimm C, Reich O, Arbyn M, Kleijnen J, Wesselmann S, Nothacker M, Follmann M, Langer T, Jentschke M.

Geburtshilfe Frauenheilkd. 2019 Feb;79(2):148-159. doi: 10.1055/a-0818-5440. Epub 2019 Feb 18.

17.

PROBAST: A Tool to Assess Risk of Bias and Applicability of Prediction Model Studies: Explanation and Elaboration.

Moons KGM, Wolff RF, Riley RD, Whiting PF, Westwood M, Collins GS, Reitsma JB, Kleijnen J, Mallett S.

Ann Intern Med. 2019 Jan 1;170(1):W1-W33. doi: 10.7326/M18-1377.

PMID:
30596876
18.

PROBAST: A Tool to Assess the Risk of Bias and Applicability of Prediction Model Studies.

Wolff RF, Moons KGM, Riley RD, Whiting PF, Westwood M, Collins GS, Reitsma JB, Kleijnen J, Mallett S; PROBAST Group†.

Ann Intern Med. 2019 Jan 1;170(1):51-58. doi: 10.7326/M18-1376.

PMID:
30596875
19.

Obinutuzumab in Combination with Chemotherapy for the First-Line Treatment of Patients with Advanced Follicular Lymphoma : An Evidence Review Group Evaluation of the NICE Single Technology Appraisal.

Thielen FW, Büyükkaramikli NC, Riemsma R, Fayter D, Armstrong N, Wei CY, Huertas Carrera V, Misso K, Worthy G, Kleijnen J, Corro Ramos I.

Pharmacoeconomics. 2019 Aug;37(8):975-984. doi: 10.1007/s40273-018-0740-4. Review.

20.

Searching Embase and MEDLINE by using only major descriptors or title and abstract fields: a prospective exploratory study.

Bramer WM, Giustini D, Kleijnen J, Franco OH.

Syst Rev. 2018 Nov 20;7(1):200. doi: 10.1186/s13643-018-0864-9.

21.

MRI-based tumor inter-fraction motion statistics for rectal cancer boost radiotherapy.

Kleijnen JJE, van Asselen B, Van den Begin R, Intven M, Burbach JPM, Reerink O, Philippens MEP, de Ridder M, Lagendijk JJW, Raaymakers BW.

Acta Oncol. 2019 Feb;58(2):232-236. doi: 10.1080/0284186X.2018.1532598. Epub 2018 Nov 16.

PMID:
30444161
22.

Arsenic Trioxide for Treating Acute Promyelocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Ramaekers BLT, Riemsma R, Grimm S, Fayter D, Deshpande S, Armstrong N, Witlox W, Pouwels X, Duffy S, Worthy G, Kleijnen J, Joore MA.

Pharmacoeconomics. 2019 Jul;37(7):887-894. doi: 10.1007/s40273-018-0738-y. Review.

23.

ROBIS: strumento per valutare il rischio di bias nelle revisioni sistematiche.

Whiting P, Savović J, Higgins JPT, Caldwell DM, Reeves BC, Shea B, Davies P, Kleijnen J, Churchill R; ROBIS Group.

Recenti Prog Med. 2018 Sep;109(9):27e-29e. doi: 10.1701/2990.29933. Italian. No abstract available.

PMID:
30303186
24.

ROBIS: guida all'uso.

Whiting P, Savović J, Higgins JPT, Caldwell DM, Reeves BC, Shea B, Davies P, Kleijnen J, Churchill R; ROBIS Group.

Recenti Prog Med. 2018 Sep;109(9):1e-26e. doi: 10.1701/2990.29932. Italian. No abstract available.

PMID:
30303185
25.

[ROBIS: a new tool to assess risk of bias in systematic reviews was developed.]

Whiting P, Savović J, Higgins JPT, Caldwell DM, Reeves BC, Shea B, Davies P, Kleijnen J, Churchill R; ROBIS Group.

Recenti Prog Med. 2018 Sep;109(9):421-431. doi: 10.1701/2990.29928. Italian.

PMID:
30303184
26.

Nivolumab for Treating Metastatic or Unresectable Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Grimm SE, Armstrong N, Ramaekers BLT, Pouwels X, Lang S, Petersohn S, Riemsma R, Worthy G, Stirk L, Ross J, Kleijnen J, Joore MA.

Pharmacoeconomics. 2019 May;37(5):655-667. doi: 10.1007/s40273-018-0723-5. Review.

PMID:
30293207
27.

Effectiveness of Primary Care Interventions Using a Biopsychosocial Approach in Chronic Low Back Pain: A Systematic Review.

van Erp RMA, Huijnen IPJ, Jakobs MLG, Kleijnen J, Smeets RJEM.

Pain Pract. 2019 Feb;19(2):224-241. doi: 10.1111/papr.12735. Epub 2018 Dec 2.

PMID:
30290052
28.

A systematic approach to searching: an efficient and complete method to develop literature searches.

Bramer WM, de Jonge GB, Rethlefsen ML, Mast F, Kleijnen J.

J Med Libr Assoc. 2018 Oct;106(4):531-541. doi: 10.5195/jmla.2018.283. Epub 2018 Oct 1.

29.

Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Büyükkaramikli NC, de Groot S, Riemsma R, Fayter D, Armstrong N, Portegijs P, Duffy S, Kleijnen J, Al MJ.

Pharmacoeconomics. 2019 Feb;37(2):141-153. doi: 10.1007/s40273-018-0708-4. Review.

30.

Risk scores to guide referral decisions for people with suspected ovarian cancer in secondary care: a systematic review and cost-effectiveness analysis.

Westwood M, Ramaekers B, Lang S, Grimm S, Deshpande S, de Kock S, Armstrong N, Joore M, Kleijnen J.

Health Technol Assess. 2018 Aug;22(44):1-264. doi: 10.3310/hta22440. Review.

31.

What's up, doc? The latest news on finding reviews.

Kleijnen J.

JBI Database System Rev Implement Rep. 2018 Jun;16(6):1284-1285. doi: 10.11124/JBISRIR-2017-003835. No abstract available.

PMID:
29894395
32.

Clinically inappropriate post hoc exclusion of study participants from test accuracy calculations: the ROMA score, an example from a recent NICE diagnostic assessment.

Lang S, Armstrong N, Deshpande S, Ramaekers B, Grimm S, de Kock S, Kleijnen J, Westwood M.

Ann Clin Biochem. 2019 Jan;56(1):72-81. doi: 10.1177/0004563218782722. Epub 2018 Jun 25.

PMID:
29848041
33.

Patient- and tumor-related predictors of chemotherapy intolerance in older patients with cancer: A systematic review.

van Abbema DL, van den Akker M, Janssen-Heijnen ML, van den Berkmortel F, Hoeben A, de Vos-Geelen J, Buntinx F, Kleijnen J, Tjan-Heijnen VCG.

J Geriatr Oncol. 2019 Jan;10(1):31-41. doi: 10.1016/j.jgo.2018.04.001. Epub 2018 Apr 26. Review.

34.

Towards a core outcome set for hemorrhoidal disease-a systematic review of outcomes reported in literature.

van Tol RR, van Zwietering E, Kleijnen J, Melenhorst J, Stassen LPS, Dirksen CD, Breukink SO.

Int J Colorectal Dis. 2018 Jul;33(7):849-856. doi: 10.1007/s00384-018-3046-2. Epub 2018 Apr 22. Review.

35.

Does setup on rectal wall improve rectal cancer boost radiotherapy?

Kleijnen JJE, van Asselen B, Intven M, Burbach JPM, Philippens MEP, Lagendijk JJW, Raaymakers BW.

Radiat Oncol. 2018 Apr 4;13(1):61. doi: 10.1186/s13014-018-1011-4.

36.

Preconception risk assessment for thalassaemia, sickle cell disease, cystic fibrosis and Tay-Sachs disease.

Hussein N, Weng SF, Kai J, Kleijnen J, Qureshi N.

Cochrane Database Syst Rev. 2018 Mar 14;3:CD010849. doi: 10.1002/14651858.CD010849.pub3. Review.

37.

Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Ramaekers BLT, Wolff RF, Pouwels X, Oosterhoff M, Van Giessen A, Worthy G, Noake C, Armstrong N, Kleijnen J, Joore MA.

Pharmacoeconomics. 2018 Aug;36(8):917-927. doi: 10.1007/s40273-018-0629-2. Review.

38.

Ticagrelor for Secondary Prevention of Atherothrombotic Events After Myocardial Infarction: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Pouwels XGLV, Wolff R, Ramaekers BLT, Van Giessen A, Lang S, Ryder S, Worthy G, Duffy S, Armstrong N, Kleijnen J, Joore MA.

Pharmacoeconomics. 2018 May;36(5):533-543. doi: 10.1007/s40273-017-0607-0. Review.

39.

Optimal database combinations for literature searches in systematic reviews: a prospective exploratory study.

Bramer WM, Rethlefsen ML, Kleijnen J, Franco OH.

Syst Rev. 2017 Dec 6;6(1):245. doi: 10.1186/s13643-017-0644-y. Review.

40.

Trifluridine-Tipiracil for Previously Treated Metastatic Colorectal Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Ramaekers BLT, Wolff R, van Giessen A, Pouwels X, Fayter D, Lang S, Armstrong N, Worthy G, Duffy S, Kleijnen J, Joore MA.

Pharmacoeconomics. 2018 Mar;36(3):285-288. doi: 10.1007/s40273-017-0591-4. Review.

41.

Tumor volume regression during preoperative chemoradiotherapy for rectal cancer: a prospective observational study with weekly MRI.

Van den Begin R, Kleijnen JP, Engels B, Philippens M, van Asselen B, Raaymakers B, Reerink O, De Ridder M, Intven M.

Acta Oncol. 2018 Jun;57(6):723-727. doi: 10.1080/0284186X.2017.1400689. Epub 2017 Nov 20.

PMID:
29157069
42.

Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of an NICE Single Technology Appraisal.

Büyükkaramikli NC, de Groot S, Fayter D, Wolff R, Armstrong N, Stirk L, Worthy G, Albuquerque de Almeida F, Kleijnen J, Al MJ.

Pharmacoeconomics. 2018 Feb;36(2):145-159. doi: 10.1007/s40273-017-0581-6. Review.

43.

Evaluation of a new method for librarian-mediated literature searches for systematic reviews.

Bramer WM, Rethlefsen ML, Mast F, Kleijnen J.

Res Synth Methods. 2018 Dec;9(4):510-520. doi: 10.1002/jrsm.1279. Epub 2017 Nov 28.

44.

Faecal immunochemical tests (FIT) can help to rule out colorectal cancer in patients presenting in primary care with lower abdominal symptoms: a systematic review conducted to inform new NICE DG30 diagnostic guidance.

Westwood M, Lang S, Armstrong N, van Turenhout S, Cubiella J, Stirk L, Ramos IC, Luyendijk M, Zaim R, Kleijnen J, Fraser CG.

BMC Med. 2017 Oct 24;15(1):189. doi: 10.1186/s12916-017-0944-z. Review.

45.

Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia.

Toth PP, Worthy G, Gandra SR, Sattar N, Bray S, Cheng LI, Bridges I, Worth GM, Dent R, Forbes CA, Deshpande S, Ross J, Kleijnen J, Stroes ESG.

J Am Heart Assoc. 2017 Oct 2;6(10). pii: e005367. doi: 10.1161/JAHA.116.005367. Review.

46.

Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Büyükkaramikli NC, Blommestein HM, Riemsma R, Armstrong N, Clay FJ, Ross J, Worthy G, Severens J, Kleijnen J, Al MJ.

Pharmacoeconomics. 2017 Dec;35(12):1211-1221. doi: 10.1007/s40273-017-0528-y. Review.

47.

Faecal immunochemical tests to triage patients with lower abdominal symptoms for suspected colorectal cancer referrals in primary care: a systematic review and cost-effectiveness analysis.

Westwood M, Corro Ramos I, Lang S, Luyendijk M, Zaim R, Stirk L, Al M, Armstrong N, Kleijnen J.

Health Technol Assess. 2017 May;21(33):1-234. doi: 10.3310/hta21330. Review.

48.

The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review.

Ryder S, Leadley RM, Armstrong N, Westwood M, de Kock S, Butt T, Jain M, Kleijnen J.

Orphanet J Rare Dis. 2017 Apr 26;12(1):79. doi: 10.1186/s13023-017-0631-3. Review.

49.

Response to Letter to the Editor Regarding "Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal".

Ramaekers BLT, Riemsma R, Tomini F, van Asselt T, Deshpande S, Duffy S, Armstrong N, Severens JL, Kleijnen J, Joore MA.

Pharmacoeconomics. 2017 Jun;35(6):665-667. doi: 10.1007/s40273-017-0507-3. No abstract available.

PMID:
28391508
50.

Can incontinence be cured? A systematic review of cure rates.

Riemsma R, Hagen S, Kirschner-Hermanns R, Norton C, Wijk H, Andersson KE, Chapple C, Spinks J, Wagg A, Hutt E, Misso K, Deshpande S, Kleijnen J, Milsom I.

BMC Med. 2017 Mar 24;15(1):63. doi: 10.1186/s12916-017-0828-2. Review.

Supplemental Content

Loading ...
Support Center